VAIKUTUS

Novel inorgano-bioorganic nanocomposites for biomedical and engineering applications

Coordinatore	HELSINGIN YLIOPISTO    more  Organization address address: YLIOPISTONKATU 4 city: HELSINGIN YLIOPISTO postcode: 14 contact info Titolo: Ms. Nome: Katariina Cognome: Vainio-Mattila Email: send email Telefono: 358919000000 Fax: 358919000000
Nazionalità Coordinatore	Finland [FI]
Totale costo	735˙800 €
EC contributo	735˙800 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2011-IRSES
Funding Scheme	MC-IRSES
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-03-01   -   2016-02-29

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	HELSINGIN YLIOPISTO  Organization address address: YLIOPISTONKATU 4 city: HELSINGIN YLIOPISTO postcode: 14 contact info Titolo: Ms. Nome: Katariina Cognome: Vainio-Mattila Email: send email Telefono: 358919000000 Fax: 358919000000	FI (HELSINGIN YLIOPISTO)	coordinator	370˙800.00
2	CONSIGLIO NAZIONALE DELLE RICERCHE  Organization address address: Piazzale Aldo Moro 7 city: ROMA postcode: 185 contact info Titolo: Ms. Nome: Floriana Cognome: Bernabucci Email: send email Telefono: 390650000000 Fax: 390650000000	IT (ROMA)	participant	365˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The principal objective of the present Project is to establish a long-lasting collaboration, to provide a possibility for transfer of knowledge, to enable exchanges of research personnel, and to create an intercontinental network in the area of hybrid inorgano-bioorganic nanocomposites for biomedical and engineering applications. Realization of the Project will lead to the development of novel nanobiocomposites, which are based on natural components specific for particular regions of Brazil and South Africa. The expertise of the consortium partners is mutually complementary, it encompasses synthesis of the nanocomposite precursors (FI), their modification and improvement of synthetic approaches to hybrid nanocomposites (UA), isolation and characterization of natural active compounds and fibres of plant origin (BR2, BR1, ZA) that are coupled with the development of advanced nanophases and hybrid nanocomposites (FI, IT1, IT2, BR1). Main scientific goal of Project consists in the development of knowledge-based high-added value inorgano-bioorganic nanocomposites, natural and nature identical materials, drug delivery vectors, pharmaceutically active compounds, pharmaceutical and cosmetic formulas through valorisation of regional natural resources and scientific expertise. Innovative nanocomposites and their novel components will be characterized using up-to-date facilities available at all partner organizations for comprehensive physico-chemical, mechanical, spectroscopic, and microscopic studies at the nano-scale; followed by assessment of their anti-cancer, anti-parasite, insecticide and antimicrobial performance in in-vitro (BR2, ZA) and in-vivo tests (ZA). Ethical issues of the research will be duly addressed. Results of the Project will strengthen the scientific potential of ERA, will contribute to the sustainable development in participating countries and promote regional development of the Partner Countries.'